HHS awards $50M contract for pandemic vaccine egg supply, highlighting critical supply chain resilience

Contract Overview

Contract Amount: $49,895,006 ($49.9M)

Contractor: Sanofi Vaccines US Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2022-02-16

End Date: 2025-01-31

Contract Duration: 1,080 days

Daily Burn Rate: $46.2K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: Healthcare

Official Description: MAINTENANCE OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE. THE ANTICIPATED CONTRACT IS INTENDED TO SATISFY THE MAINTENANCE OF A RAW MATERIAL SUPPLY CHAIN OF EMBRYONATED HEN EGGS, IN SUPPORT OF A U.S.-LICENSED PANDEMIC INFL

Place of Performance

Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $49.9 million to SANOFI VACCINES US INC. for work described as: MAINTENANCE OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE. THE ANTICIPATED CONTRACT IS INTENDED TO SATISFY THE MAINTENANCE OF A RAW MATERIAL SUPPLY CHAIN OF EMBRYONATED HEN EGGS, IN SUPPORT OF A U.S.-LICENSED PANDEMIC INFL Key points: 1. Contract ensures a stable supply of embryonated eggs, a key component for vaccine production. 2. Focus on non-seasonal production indicates preparedness for unexpected public health crises. 3. Sole-source award suggests limited market options or a strategic partnership for this specific need. 4. Contract duration of 3 years provides long-term stability for this essential service. 5. The fixed fee component of the cost-plus contract offers some predictability in contractor profit. 6. Geographic location in Pennsylvania may indicate a concentration of related biopharmaceutical infrastructure.

Value Assessment

Rating: good

The contract's value of approximately $50 million over three years for maintaining a critical raw material supply chain appears reasonable given the strategic importance of pandemic preparedness. Benchmarking this specific service is challenging due to its niche nature, but the cost-plus-fixed-fee structure allows for cost transparency while incentivizing efficient delivery. The awarded amount is within the expected range for securing such a specialized and vital component of vaccine manufacturing.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, indicating that the government identified a unique capability or necessity that could not be met through a competitive process. This approach is often employed for specialized services where only one or a very limited number of contractors possess the required expertise, facilities, or existing infrastructure. The lack of competition means that price discovery through market forces was not a primary factor in this award.

Taxpayer Impact: Sole-source awards can potentially lead to higher costs for taxpayers as competitive pressures are absent. However, in critical areas like pandemic preparedness, the assurance of supply and specialized capability may outweigh the potential cost savings from competition.

Public Impact

The primary beneficiaries are the U.S. public, through enhanced preparedness for pandemic vaccine production. The contract ensures the availability of embryonated hen eggs, a fundamental input for vaccine manufacturing. The geographic impact is primarily national, focusing on the security of the U.S. vaccine supply chain. Workforce implications may include specialized roles in biopharmaceutical manufacturing and supply chain management within the contractor's organization.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source nature limits transparency in pricing and potential for cost savings.
Reliance on a single supplier for a critical component introduces supply chain risk.
Contract duration may not align with evolving pandemic response strategies.

Positive Signals

Ensures critical raw material availability for pandemic vaccine production.
Supports long-term supply chain resilience for public health emergencies.
Fixed fee provides some cost certainty for the government.

Sector Analysis

The pharmaceutical preparation manufacturing sector is highly specialized, with significant barriers to entry due to regulatory requirements, research and development costs, and the need for advanced manufacturing capabilities. This contract fits within the broader biopharmaceutical industry's role in supporting national health security. Comparable spending benchmarks are difficult to establish for such a niche supply chain component, but investments in pandemic preparedness are increasing globally.

Small Business Impact

This contract does not appear to involve small business set-asides, nor are there explicit indications of subcontracting opportunities for small businesses. The specialized nature of embryonated egg production for vaccine manufacturing likely requires large-scale, established facilities and expertise, which are typically found in larger corporations within the biopharmaceutical sector. The impact on the small business ecosystem is likely minimal for this specific award.

Oversight & Accountability

Oversight for this contract will likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Accountability measures are embedded in the cost-plus-fixed-fee structure, requiring the contractor to justify costs and deliver on agreed-upon milestones. Transparency is facilitated through contract reporting requirements, though the sole-source nature limits public insight into the competitive bidding process.

Related Government Programs

Pandemic Preparedness Initiatives
Biopharmaceutical Supply Chain Security
Vaccine Manufacturing Support
Strategic National Stockpile

Risk Flags

Sole-source award lacks competitive pricing.
Potential for supply chain disruption if contractor faces issues.
Dependence on a single supplier for a critical national security asset.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $49.9 million to SANOFI VACCINES US INC.. MAINTENANCE OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE. THE ANTICIPATED CONTRACT IS INTENDED TO SATISFY THE MAINTENANCE OF A RAW MATERIAL SUPPLY CHAIN OF EMBRYONATED HEN EGGS, IN SUPPORT OF A U.S.-LICENSED PANDEMIC INFL

Who is the contractor on this award?

The obligated recipient is SANOFI VACCINES US INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $49.9 million.

What is the period of performance?

Start: 2022-02-16. End: 2025-01-31.

What is the track record of Sanofi Vaccines US Inc. in supplying critical raw materials for vaccine production, particularly during public health emergencies?

Sanofi is a major global pharmaceutical company with extensive experience in vaccine development and manufacturing. While specific details on their track record for supplying embryonated eggs as a raw material for pandemic vaccines are not publicly detailed in this contract's data, the company's broader portfolio includes numerous vaccines, indicating established capabilities in related areas. Their involvement in pandemic response efforts, such as supplying COVID-19 vaccines, suggests a capacity to scale production and manage complex supply chains. Further investigation into their historical performance with government contracts, especially those related to emergency preparedness and vaccine components, would provide a more comprehensive assessment of their reliability for this specific need.

How does the awarded amount of approximately $50 million compare to historical spending on similar raw material supply contracts for vaccine production?

Direct comparisons for the specific service of 'maintenance of embryonated egg supply for non-seasonal production of pandemic vaccine' are challenging due to the niche nature of the requirement and the strategic focus on pandemic preparedness. However, government investments in biopharmaceutical supply chains and vaccine development have seen significant increases, particularly post-COVID-19. Contracts for raw materials and essential components for vaccine manufacturing can range widely depending on volume, duration, and complexity. Given the three-year duration and the critical nature of ensuring a non-seasonal supply for potential pandemic use, the $50 million figure appears to be a strategic investment rather than a routine procurement, making direct historical spending comparisons difficult without more granular data on similar pandemic-focused raw material contracts.

What are the primary risks associated with a sole-source award for a critical component like embryonated eggs, and how are these risks mitigated?

The primary risks of a sole-source award include potential overpricing due to the absence of competitive bidding, reduced incentive for innovation, and increased vulnerability if the sole supplier faces operational issues. For this contract, the government mitigates these risks through the Cost Plus Fixed Fee (CPFF) contract type, which allows for cost transparency and a defined profit margin, providing some control over expenditures. The government also likely has robust oversight mechanisms, including regular performance reviews and audits, to ensure the contractor meets quality standards and delivery schedules. Furthermore, the strategic importance of this supply chain component may lead the government to maintain close communication and potentially explore alternative suppliers or develop in-house capabilities as a long-term mitigation strategy.

How effective is the Cost Plus Fixed Fee (CPFF) contract structure in ensuring value for money for this specific type of specialized supply chain service?

The CPFF structure aims to balance cost control with the need for specialized services where precise cost estimation might be difficult upfront. For maintaining a critical raw material supply chain like embryonated eggs for pandemic vaccines, where unforeseen challenges can arise, CPFF allows flexibility. The 'fixed fee' component provides the contractor with a predetermined profit, incentivizing them to complete the work efficiently to maximize their return without necessarily driving up costs excessively. The government benefits from insight into incurred costs, enabling oversight and negotiation. While it may not always yield the absolute lowest price compared to a fixed-price contract in a highly competitive market, it is often considered effective for complex, R&D-intensive, or specialized services where scope or cost certainty is limited, thus promoting value by ensuring the critical service is delivered.

What are the implications of the contract's duration (3 years) for the government's long-term pandemic preparedness strategy?

A three-year contract duration provides a stable and predictable supply of embryonated eggs, which is crucial for maintaining readiness for potential pandemic vaccine production. This timeframe allows for consistent operations and quality control by the contractor, ensuring the raw material is available when needed. From a strategic perspective, this duration suggests a commitment to bolstering the vaccine supply chain infrastructure. However, it also implies that the government will need to re-evaluate its needs and potentially re-compete or extend the contract beyond this period. A longer-term strategy might involve diversifying suppliers or investing in domestic production capabilities, but this three-year contract serves as a vital interim measure to secure a critical component.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL SERVICES › OTHER MEDICAL SERVICES

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: N/A

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Sanofi

Address: 1 DISCOVERY DR, SWIFTWATER, PA, 18370

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $49,895,006

Exercised Options: $49,895,006

Current Obligation: $49,895,006

Actual Outlays: $48,953,046

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline